Strides Pharma Science arm gets USFDA nod for ethacrynic acid tablets


Pharmaceutical company Strides Pharma Science said on Tuesday that its resigning subsidiary had received approval from the U.S. health regulator for ethacrynic acid tablets, used to treat fluid retention (edema).

The approved product is a generic version of Edecrin 25 mg tablets from Bausch Health Americas.

Strides Pharma Global, Singapore, has received approval for Ethacrynic Acid Tablets USP in strengths of 25 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science has reported in a regulatory filing.

Citing the August 2020 IQVIA Annual Moving Total (MAT) data, Strides Pharma Science said the US market for Ethacrynic Acid Tablets USP, 25 mg, is approximately $ 14 million.

The product will be manufactured at the company’s flagship plant in Bengaluru and will be marketed by Strides Pharma in the US market, the company added.

The company has 126 cumulative Abbreviated New Drug Application (ANDA) filings with the USFDA, of which 92 ANDAs have been approved and 34 are pending approval.

Ethacrynic acid belongs to a class of medicines called diuretics (water pills). It is used to treat edema (excess fluid in body tissue) in adults and children caused by medical problems such as cancer, heart disease, kidney disease or liver disease.

Shares of Strides Pharma Science were trading 0.95% higher at Rs 753.60 each on BSE.

(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that are of interest to you and which have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times stemming from Covid-19, we continue to remain committed to keeping you informed and up to date with credible news, authoritative opinions and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with higher quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscribing to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

Digital editor

Leave A Reply

Your email address will not be published.